Tori Whitacre Martonicz, MA, is the lead editor of Infection Control Today. She has been a writer and editor for over 30 years and has an MA and BA in English Composition/Literature from the University of Akron in Akron, OH. She lives in Ohio with her husband, Eric; son, Drake; 2 tiny dogs, Selena Brigid Sophia and Doctor Danger Dog; and a big black cat, Freya. She loves reading, writing, gardening, and spending time with her loved ones.
Contact her through her email: tmartonicz@mjhlifesciences.com.
Recent CDC HICPAC revisions regarding SARS-CoV-2 control face criticism from the World Health Network and others due to alleged breaches in committee structure and erroneous infection control guidance, potentially impacting COVID-19 management and immunocompromised individuals in health care.
Kari A. Mergenhagen, PharmD, BCPS, BCIDP, discusses the potential of doxycycline in reducing C difficile infections among hospitalized patients with pneumonia. This interview delves into doxycycline's influence on patients with a prior C difficile history, demographic generalizability, exclusion criteria, and concerns regarding antibiotic resistance.
Pharmaceutical company Qnovia partners with the University of Virginia (UVA) to create inhaled drugs for lung infections, bolstering their development pipeline with assets for pneumonia and biodefense-related pulmonary infections.
A study led by Piyali Chatterjee, PhD, and the Central Texas Veterans Health Care System explores the potential of handheld filtered Far UV-C devices in reducing hospital-acquired infections. Freestyle Partners, LLC, supported this research.
A recent American Journal of Infection Control study, led by Katharine Hoffman, MPH, CIC, LSSGB, and Lisa Waldowski, DNP, RN, CIC, applies Lean Six Sigma to improve eye device reprocessing. The research highlights the challenges, emphasizes adherence to manufacturer instructions, and promotes best practices for patient safety.
Benjamin Chen, MD, MPH, speaks about how a journal watch in infection prevention keeps professionals updated on research, fosters evidence-based practices, and supports education and quality improvement efforts.
ICT speaks with Christopher Reid, PhD, a biological and biomedical Sciences professor, delving into his investigations on antibiotics and fungicides and how his team's investigations will "provide an extra tool in a clinician's" toolbox for treating bacterial fungal infections."
“Celebrate Clean Hospitals Day with us. We're an association that is trying to get out there and make people's lives a bit safer and better. Join us!” Alexandra Peters, PhD
Recent INFORM and EPOCH studies shed light on the significant risk and poor outcomes faced by immunocompromised individuals due to COVID-19, emphasizing the need for tailored prevention strategies.
Infection Control Today analyzes the surprising findings from its recent informal survey on the minimum educational requirement for infection preventionists.
In an interview with Amy Spallone, MD, from The University of Texas MD Anderson Cancer Center, the study investigates the effects of COVID-19 precautions on healthcare-associated infections, revealing surprising results in central line-associated bloodstream infections (CLABSIs), C difficile infections, and more.
International Infection Prevention and Control Week highlights the importance of preventing infections in health care and other settings. Share this poem to help educate others about IPC.
A study in Maryland from June 2019 to December 2021 analyzed 140 Candida auris cases, revealing that patients often resided in disadvantaged neighborhoods with higher crowding, uninsured rates, and racial diversity. ICT speaks to the lead author.
Dr. Isaac Kohane explores AI's rapid medical evolution and the challenges of accuracy, updating, and education in infectious diseases at IDWeek 2023.
BiomX Develops BX004-A, a Phage Therapy, for Cystic Fibrosis Patients with Pseudomonas Infections. A phase 1b/2a study presents promising results at IDWeek 2023.
The investigational mRNA-1647 vaccine discussed at IDWeek 2023 shows great promise in the fight against cytomegalovirus (CMV) infection. Developed using messenger RNA technology, it incorporates essential CMV antigens and has demonstrated safety and effectiveness in clinical evaluations.
An 18-month trial with 801,668 ICU admissions showed that mupirocin nasal ointment effectively reduces Staphylococcus aureus and MRSA infections by 18% and 15% respectively, offering hope in ICU infection prevention.
Fibi Attia, MD, MP, CIC, and her colleagues conducted a study on multisystem inflammatory syndrome in children (MIS-C) linked to COVID-19. The study focused on the characteristics, implications, and outcomes of MIS-C cases, particularly cardiac dysfunction. The interview discusses the study's goals and key findings, stressing the importance of detecting MIS-C cases and the need for more research on COVID-19 vaccines.
Eco-friendly cleaners and disinfectants are important for sustainability in health care settings. They are biodegradable, have a reduced impact on ecosystems, and promote cleaner indoor air quality, all of which are especially important to the younger generations.
As COVID-19 restrictions eased up, other respiratory viruses began circulating alongside SARS-CoV-2. It's crucial to identify cases and understand the symptoms of these infections to track the evolution of the virus and what health care workers should look out for.
Take 5 minutes to catch up on Infection Control Today®’s highlights for the week ending September 24, 2023.
Deborah Birx, MD, highlights concerns about the lack of data-driven action in the fight against COVID-19. She emphasizes the need for timely alerts and empowering communities to protect vulnerable individuals.
Deborah Birx, MD, discusses the significance of collaboration, innovation, data-driven decision-making, and community engagement in public health. Her insights underscore the need for trust-building and adaptability in pandemic response.
Doe Kley, MPH, RN, T-CHEST, LTC-CIP, CIC, speaks to Infection Control Today about her presentation and other exceptional presentations at the Association for the Health Care Environment (AHE) Exchange Conference & Solution Center
A new preventative vaccine has been developed incorporating technology funded by the NIH since 2004. The trials will be conducted in the United States and South Africa.
The AHE Exchange Conference in Dallas focused on emerging pathogens and the role of environmental services. Doe Kley, MPH, RN, T-CHEST, LTC-CIP, CIC, discusses hers and other exceptional presentations with Infection Control Today.
Ambassador Deborah Birx, MD, discusses whether students should be required to wear masks to protect themselves and others and what the public should know about the newest COVID-19 variant, B.A.2.86.
The Healthy People 2030 initiative aims to improve the health of the United States’ population through research and developmental objectives through the end of the decade.
Ambassador Deborah Birx, MD, answers the persistent question of whether mRNA technology is safe in the long term.
“Once people started to get infected and reinfected despite being vaccinated, their interpretation then is this vaccine doesn't work…. But [the COVID-19 vaccine] was never designed, studied, tested, or released to protect against infection.” --Ambassador Deborah Birx, MD